{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:34:28Z","timestamp":1787776468910,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Marburg\u2019s disease is a fatal variant of multiple sclerosis (MS), distinguished by its fulminant, rapidly progressive monophasic course that often leads to patients\u2019 mortality within weeks of onset. Owing to its rarity, there are no established treatment guidelines. We present a 34 year-old male who was diagnosed with MS, and magnetic resonance imaging revealed numerous supra- and infratentorial white matter plaques. Steroid pulse therapy, intravenous immunoglobulin, and plasma exchange were ineffective. After excluding other differential diagnoses, Marburg\u2019s variant MS was considered, and intravenous cyclophosphamide with methylprednisolone was administered. The patient showed significant and fast clinical improvement adding to the evidence that cyclophosphamide is an effective therapeutic modality for treating this MS variant.<\/jats:p>","DOI":"10.4103\/aam.aam_30_24","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:00:09Z","timestamp":1748606409000},"page":"686-690","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A Patient with Marburg\u2019s Variant of Multiple Sclerosis Responded Well to Cyclophosphamide"],"prefix":"10.4103","volume":"24","author":[{"given":"Foziah Jabbar","family":"Alshamrani","sequence":"first","affiliation":[{"name":"Department of Neurology, King Fahad University Hospital, Al Khobar, Saudi Arabia"},{"name":"Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan Salim","family":"Alyami","sequence":"additional","affiliation":[{"name":"Department of Neurology, King Fahad University Hospital, Al Khobar, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"R1-20260422","first-page":"211","article-title":"Acute multiple sclerosis (encephalomyelitis pariaxialis scleroticans)","volume":"27","author":"Marburg","year":"1906","journal-title":"J Psychiatry Neurol"},{"key":"R2-20260422","first-page":"48","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: A critical review","author":"Karussis","year":"2014","journal-title":"J Autoimmun"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864211006503","article-title":"Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: A retrospective analysis of 50 consecutive cases","volume":"14","author":"Vakrakou","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.25807","article-title":"COVID-19: A global threat to the nervous system","volume":"88","author":"Koralnik","year":"2020","journal-title":"Ann Neurol"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1212\/WNL.0000000000002825","article-title":"Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"117570","DOI":"10.1016\/j.jns.2021.117570","article-title":"Bal\u00f3\u2019s concentric sclerosis \u2013 A rare entity within the spectrum of demyelinating diseases","volume":"428","author":"Xie","year":"2021","journal-title":"J Neurol Sci"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2010.05.022","article-title":"High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report","volume":"296","author":"Nozaki","year":"2010","journal-title":"J Neurol Sci"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40120-021-00308-6","article-title":"Marburg multiple sclerosis variant: Complete remission with very early administration of mitoxantrone-a case report","volume":"11","author":"Capet","year":"2022","journal-title":"Neurol Ther"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/aian.AIAN_117_20","article-title":"A case of Marburg\u2019s variant of multiple sclerosis successfully treated with IVIg and mitoxantrone","volume":"24","author":"Manuel","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1552-6569.2004.tb00217.x","article-title":"Treatment of marburg variant multiple sclerosis with mitoxantrone","volume":"14","author":"Jeffery","year":"2004","journal-title":"J Neuroimaging"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.msard.2017.06.007","article-title":"A case of acute fulminant multiple sclerosis treated with alemtuzumab","volume":"17","author":"Gobbin","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp.53.10.918","article-title":"Fulminant monophasic multiple sclerosis, Marburg\u2019s type","volume":"53","author":"Johnson","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410400106","article-title":"Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein","volume":"40","author":"Wood","year":"1996","journal-title":"Ann Neurol"},{"issue":"17_supplement_2","key":"R14-20260422","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1212\/WNL.0000000000203000","article-title":"High-dose cyclophosphamide as a rescue treatment for fulminant Marburg multiple sclerosis: A case report (P12-3.014)","volume":"100","author":"Roberts","year":"2023","journal-title":"Neurology"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"696807","DOI":"10.3389\/fneur.2021.696807","article-title":"Case report: Successful stabilization of Marburg variant multiple sclerosis with ocrelizumab following high-dose cyclophosphamide rescue","volume":"12","author":"Koska","year":"2021","journal-title":"Front Neurol"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2019.03.014","article-title":"An extremely aggressive case of Marburg\u2019s disease treated with high dose cyclophosphamide. A case report","volume":"31","author":"Avila-Ornelas","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10072-010-0287-4","article-title":"Long survival and clinical stability in Marburg\u2019s variant multiple sclerosis","volume":"31","author":"Turatti","year":"2010","journal-title":"Neurol Sci"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneurol.65.8.noc80042","article-title":"Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis","volume":"65","author":"Krishnan","year":"2008","journal-title":"Arch Neurol"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archneur.63.10.noc60076","article-title":"High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis","volume":"63","author":"Gladstone","year":"2006","journal-title":"Arch Neurol"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide toxicity. Characterising and avoiding the problem","volume":"42","author":"Fraiser","year":"1991","journal-title":"Drugs"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_30_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:10:44Z","timestamp":1787775044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_30_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_30_24","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"2024-02-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}